New combo therapy offers hope for kidney cancer patients who relapsed
NCT ID NCT07460206
First seen Mar 15, 2026 · Last updated May 06, 2026 · Updated 5 times
Summary
This study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink or slow advanced kidney cancer in 108 adults whose cancer returned after prior pembrolizumab treatment. Participants receive the drug combination and are monitored for tumor response and side effects. The goal is to find a new treatment option for this hard-to-treat situation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CCRCC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.